Asymptomatic Multiple Myeloma Masquerading as Accidental Fracture
Keywords:
Multiple Myeloma, Fracture, Plasma CellsAbstract
Multiple myeloma (MM) is a disease caused by the diffuse, uncontrolled proliferation of plasma cells. Recent estimates indicate that nearly 140,000 new cases are diagnosed each year worldwide. The presenting symptoms have usually been severe bone pain, osteolytic bone damage and pathologic fractures, hypercalcemia, kidney damage, compromised
immune function, and anaemia. We report two cases of multiple myeloma, which presented as fractures following an accident. Biopsy of both cases showed multiple fragments of bone mixed with fibro collagenous tissue and sheets of mature and immature plasma cells. Both cases were diagnosed as cases of multiple myeloma, which presented with pathological fractures. Their treatment was started immediately.
How to cite this article:
Gill G, Chauhan T, Puri SS. Asymptomatic Multiple Myeloma Masquerading as Accidental Fracture. Rec Adv Path Lab Med. 2020;7(3&4):4-6.
DOI: https://doi.org/10.24321/2454.8642.202106
References
Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016; 16:427.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548.
Thorsteinsdottir S, Gislason G, Aspelund T, Sverrisdottir I, Landgren O, Turesson I, Björkholm M, Kristinsson SY. Fractures and survival in multiple myeloma: results from a population-based study. Haematologica. 2020 Apr;105(4):1067-1073. doi:10.3324/haematol.2019.230011. Epub 2019 Dec 2. PMID: 31792034; PMCID: PMC7109735.
Ong F, Hermans J, Noordijk EM, et al. Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma associated symptoms. Ann Hematol 1995;70:149–52.
Melton LJ, Kyle RA, Achenbach SJ, et al. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005;20:487–93.
He Y, Wheatley K, Clark O, et al. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev 2003;1:CD004023.
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376:1311–20
Michels TC, Petersen KE. Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician. 2017 Mar 15;95(6):373-383. PMID: 28318212.
Kehrer M, Koob S, Strauss A, Wirtz DC, Schmolders J. Multiples Myelom – aktuelle Standards in Diagnostik und Therapie [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy]. Z Orthop Unfall. 2017 Oct;155(5):575-586. German. doi: 10.1055/s-0043-110224. Epub 2017 Aug 14. PMID: 28806822.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Recent Advances in Pathology and Laboratory Medicine ( ISSN: 2454-8642 )
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
